search
Back to results

Stem Cell Transplantation for Fanconi Anemia

Primary Purpose

Fanconi Anemia

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Hematopoietic Stem Cell Transplant
Thymic Shielding During Radiation
Total Body Irradiation
Cyclophosphamide, Fludarabine
Sponsored by
Masonic Cancer Center, University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fanconi Anemia focused on measuring Stem Cell Transplant, Thymic Shielding, Total Body Irradiation, Chemotherapy

Eligibility Criteria

1 Day - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients must be less than (<) 18 years of age with a diagnosis of Fanconi anemia. Patients must have an HLA-A, B, DRB1 identical unrelated donor or less than or equal to (≤)1 antigen mismatched related (non-HLA-matched sibling) or <1 antigen mismatched unrelated UCB donor. Patients and donors will be typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. Patients with FA must have aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below. Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions Platelet count <20 x 10^9/L ANC <5 x 10^8/L Hgb <8 g/dL Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations) Adequate major organ function including Cardiac: ejection fraction greater than (>)45% Hepatic: bilirubin, AST/ALT, ALP <2 x normal Karnofsky performance status >70% or Lansky performance status >50% Women of child-bearing age must be using adequate birth control and have a negative pregnancy test Exclusion Criteria: Available HLA-genotypically identical related donor History of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies) Refractory anemia with excess blasts, or leukemia Active central nervous system (CNS) leukemia at time of hematopoietic cell transplant (HCT) History of squamous cell carcinoma of the head/neck/cervix within 2 years of HCT Pregnant or lactating female Prior radiation therapy preventing use of total body irradiation (TBI) 450 centigray (cGy)

Sites / Locations

  • Masonic Cancer Center, University of Minnesota

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HSCT Patients

Arm Description

Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)

Outcomes

Primary Outcome Measures

Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment
Calculated from Day 1 of hematopoietic cell transplant to Day 42 post-transplant. Hematopoietic recovery and engraftment is defined as the first of three consecutive days the patient's absolute neutrophil count is greater than or equal to 0.5X10^9/Liter.

Secondary Outcome Measures

Number of Patients Who Exhibited Secondary Graft Failure
Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. A complication after Bone Marrow Transplant in which the transplanted stem cells do not grow in the recipient's bone marrow and thus do not produce new blood cells.
Number of Patients With Acute Graft Versus-Host Disease (aGVHD)
Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Number of Patients With Chronic Graft Versus-Host Disease (GVHD)
Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Number of Patients Who Exhibited Regimen-related Toxicity (RRT)
Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. Regimen-related toxicity involves harmful effects in an organism through exposure to the treatment given.
Immune Reconstitution - Mean Value (1 Year)
Calculated mean value of patient CD4 values collected at intervals from Day 30 through 1 year post-transplant.
Immune Reconstitution - Mean Value (2 Years)
Calculated mean value of patient CD4 values collected at intervals from Day 30 through 2 years post-transplant.
Number of Patients Alive at 1 Year
Calculated from Day 1 of hematopoietic cell transplant to 1 year post-transplant.
Number of Patients Alive at 2 Years
Calculated from Day 1 of hematopoietic cell transplant to 2 years post-transplant.

Full Information

First Posted
September 9, 2005
Last Updated
August 21, 2019
Sponsor
Masonic Cancer Center, University of Minnesota
search

1. Study Identification

Unique Protocol Identification Number
NCT00167206
Brief Title
Stem Cell Transplantation for Fanconi Anemia
Official Title
A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Terminated
Why Stopped
Treatment with thymic shielding found safe, another study started.
Study Start Date
March 2004 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Masonic Cancer Center, University of Minnesota

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.
Detailed Description
All subjects will be given the same treatment regimen of total body irradiation (TBI), Fludarabine, Cyclophosphamide, and anti-thymocyte globulin (ATG), followed by an alternate donor stem cell transplant. Since this treatment regimen has been given before, without thymic shielding, we will compare the outcomes of these patients with the historical data from subjects who did not receive thymic shielding.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fanconi Anemia
Keywords
Stem Cell Transplant, Thymic Shielding, Total Body Irradiation, Chemotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HSCT Patients
Arm Type
Experimental
Arm Description
Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
Intervention Type
Procedure
Intervention Name(s)
Hematopoietic Stem Cell Transplant
Other Intervention Name(s)
Bone Marrow Transplant
Intervention Description
Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
Intervention Type
Procedure
Intervention Name(s)
Thymic Shielding During Radiation
Other Intervention Name(s)
TBI
Intervention Description
protecting the thymus during total body radiation (450 cGy administered)
Intervention Type
Procedure
Intervention Name(s)
Total Body Irradiation
Other Intervention Name(s)
Radiation Therapy, Therapuetic Radiation
Intervention Description
Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide, Fludarabine
Other Intervention Name(s)
Cytoxan, Fludara
Intervention Description
Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
Primary Outcome Measure Information:
Title
Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment
Description
Calculated from Day 1 of hematopoietic cell transplant to Day 42 post-transplant. Hematopoietic recovery and engraftment is defined as the first of three consecutive days the patient's absolute neutrophil count is greater than or equal to 0.5X10^9/Liter.
Time Frame
Day 42 after hematopoietic cell transplant
Secondary Outcome Measure Information:
Title
Number of Patients Who Exhibited Secondary Graft Failure
Description
Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. A complication after Bone Marrow Transplant in which the transplanted stem cells do not grow in the recipient's bone marrow and thus do not produce new blood cells.
Time Frame
Day 100 after hematopoietic cell transplant
Title
Number of Patients With Acute Graft Versus-Host Disease (aGVHD)
Description
Calculated from Day 1 of hematopoietic cell transplant to Day 100 after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Time Frame
Day 100 after hematopoietic cell transplant
Title
Number of Patients With Chronic Graft Versus-Host Disease (GVHD)
Description
Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Time Frame
1 year after hematopoietic cell transplant
Title
Number of Patients Who Exhibited Regimen-related Toxicity (RRT)
Description
Calculated from Day 1 of hematopoietic cell transplant to 1 year after transplant. Regimen-related toxicity involves harmful effects in an organism through exposure to the treatment given.
Time Frame
1 year after hematopoietic cell transplant
Title
Immune Reconstitution - Mean Value (1 Year)
Description
Calculated mean value of patient CD4 values collected at intervals from Day 30 through 1 year post-transplant.
Time Frame
1 year post-transplant.
Title
Immune Reconstitution - Mean Value (2 Years)
Description
Calculated mean value of patient CD4 values collected at intervals from Day 30 through 2 years post-transplant.
Time Frame
at 2 years after transplant
Title
Number of Patients Alive at 1 Year
Description
Calculated from Day 1 of hematopoietic cell transplant to 1 year post-transplant.
Time Frame
1 year after transplant
Title
Number of Patients Alive at 2 Years
Description
Calculated from Day 1 of hematopoietic cell transplant to 2 years post-transplant.
Time Frame
2 years after transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must be less than (<) 18 years of age with a diagnosis of Fanconi anemia. Patients must have an HLA-A, B, DRB1 identical unrelated donor or less than or equal to (≤)1 antigen mismatched related (non-HLA-matched sibling) or <1 antigen mismatched unrelated UCB donor. Patients and donors will be typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. Patients with FA must have aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below. Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions Platelet count <20 x 10^9/L ANC <5 x 10^8/L Hgb <8 g/dL Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations) Adequate major organ function including Cardiac: ejection fraction greater than (>)45% Hepatic: bilirubin, AST/ALT, ALP <2 x normal Karnofsky performance status >70% or Lansky performance status >50% Women of child-bearing age must be using adequate birth control and have a negative pregnancy test Exclusion Criteria: Available HLA-genotypically identical related donor History of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies) Refractory anemia with excess blasts, or leukemia Active central nervous system (CNS) leukemia at time of hematopoietic cell transplant (HCT) History of squamous cell carcinoma of the head/neck/cervix within 2 years of HCT Pregnant or lactating female Prior radiation therapy preventing use of total body irradiation (TBI) 450 centigray (cGy)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margaret MacMillan, MD
Organizational Affiliation
Masonic Cancer Center, University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
Masonic Cancer Center, University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25824692
Citation
MacMillan ML, DeFor TE, Young JA, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 2015 Jun 11;125(24):3798-804. doi: 10.1182/blood-2015-02-626002. Epub 2015 Mar 30.
Results Reference
derived

Learn more about this trial

Stem Cell Transplantation for Fanconi Anemia

We'll reach out to this number within 24 hrs